According to the National Health Service, cystitis is defined as the inflammation of the bladder, which is usually caused by a bladder infection. A urinary tract infection happens when bacteria enters the urethra or bladder, and begins to multiply, leading to infection. This infection could also happen when the naturally occurring bacteria in the body becomes imbalanced. The bacteria leads to an infection and causes inflammation. There are also other chances of causing cystitis, other than infection. As an example, specific medicines and hygiene products may also cause inflammation. The cystitis can affect anyone, but occurs more in women than men.
The prevalence of urinary tract infections (UTI) is rising each, year and it is estimated that in the United States, approximately 6 million patient visits physicians each year, with UTIs. According to the National Kidney Foundation, it is estimated that one in five women will have at least one UTI in their lifetime. Nearly 20% of women who have a UTI will have another, and 30% of those will have yet another. Given the rising prevalence associated with cystitis, advances are needed for patients worldwide.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence